Form 4: Evolent Health CEO Seth Blackley Reports Stock Transactions

CEO Seth Blackley reports acquisition of restricted stock units and disposal of shares to cover tax obligations.

Summary

• On March 1, 2024, Seth Blackley, CEO of Evolent Health, Inc., acquired 29,096 shares of Class A Common Stock.
• These shares were granted as restricted stock units under the company's 2015 Omnibus Incentive Compensation Plan.
• Also on March 1, 2024, Mr. Blackley disposed of 24,005 shares of Class A Common Stock at a price of $34.41.
• This disposal was to satisfy tax withholding obligations upon the vesting of restricted stock units.
• Following these transactions, Mr. Blackley beneficially owns 760,382 shares of Class A Common Stock.
• The restricted stock units vest in three tranches: 34% on March 1, 2025, and 33% on March 1, 2026, and March 1, 2027.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock transactions, with no inherent positive or negative sentiment.

Positives

• The grant of restricted stock units to the CEO aligns his interests with the long-term performance of the company.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, allowing investors to track executive compensation and potential alignment with company performance.

Comparison to Industry Standards

• Stock-based compensation is a common practice among publicly traded companies to incentivize executives.
• Vesting schedules, like the one described (34% in year 1, 33% in years 2 and 3), are typical for restricted stock unit grants.
• Companies like UnitedHealth Group and Humana also utilize stock-based compensation as part of their executive compensation packages.

Stakeholder Impact

• Shareholders can monitor insider transactions to gain insights into management's perspective on the company's value.

Key Dates